CAT And Abbott Settle Humira Royalties Dispute

Law360, New York (October 26, 2005, 12:00 AM EDT) -- Cambridge Antibody Technologies and Abbott Laboratories have ended their protracted dispute over royalties for cholesterol drug Humira, reaching a settlement just one day before a lawsuit was scheduled to begin.

Abbott will pay U.K. biotech company CAT $255 million up front, to be supplemented by five annual payments of $9.375 million beginning in January 2006.

CAT will distribute the $255 million to its licensors, including the Medical Research Council, Scripps Institute, and Stratagene, as payment for the royalties the companies stood to collect. The licensors will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.